References
- Cohen J. The scientific challenge of hepatitis C. Science 1999;285:26–30
- Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29:74–81
- Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55
- Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350–9
- Chang MH, Gordon LA, Fung HB. Boceprevir: a protease inhibitor for the treatment of hepatitis C. Clin Ther 2012;34:2021–38
- Forestier N, Zeuzem S. Telaprevir for the treatment of hepatitis C. Expert Opin Pharmacother 2012;13:593–606
- Kwong AD, McNair L, Jacobson I, George S. Recent progress in the development of selected hepatitis C virus NS3/4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol 2008;8:522–31
- Sulkowski MS. Specific targeted antiviral therapy for hepatitis C. Curr Gastroenterol Rep 2007;9:5–13
- Simmonds P. Genetic diversity and evolution of hepatitis C virus: 15 years on. J Gen Virol 2004;85:3173–88
- Legrand-Abravanel F, Nicot F, Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opin Invest Drugs 2010;19:963–75
- Beaulieu PL. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infection. Curr Opin Invest Drugs 2007;8:614–34
- Joyce CM, Steitz TA. Polymerase structures and function: variations on a theme? J Bacteriol 1995;177:6321–9
- Ludmerer SW, Graham DJ, Boots E, et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005;49:2059–69
- Zhang L, Sedykh A, Tripathi A, et al. Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches. Toxicol Appl Pharm 2013;272:67–76
- Melagraki G, Afantitis A, Sarimveis H, et al. In silico exploration for identifying structure-activity relationship of MEK inhibition and oral bioavailability for isothiazole derivatives. Chem Biol Drug Des 2010;76:397–406
- Tzanetou E, Liekens S, Kasiotis KM, et al. Antiproliferative novel isoxazoles: modeling, virtual screening, synthesis, and bioactivity evaluation. Eur J Med Chem 2014;81:139–49
- Kim K, Kim ND, Seong B. Pharmacophore-based virtual screening: a review of recent applications. Expert Opin Drug Discov 2010;5:205–22
- Ma D-L, Chan DS-H, Leung C-H. Drug repositioning by structure-based virtual screening. Chem Soc Rev 2013;42:2130–41
- Yang H, Zhong H-J, Leung K-H, et al. Structure-based design of flavone derivatives as c-myc oncogene down-regulators. Eur J Pharm Sci 2013;48:130–41
- Leung C-H, Chan DS-H, Li Y-W, et al. Hit identification of IKKβ natural product inhibitor. BMC Pharmacol Toxicol 2013;14:3
- Ma D-L, Ma VP-Y, Chan DS-H, et al. In silico screening of quadruplex-binding ligands. Methods 2012;57:106–14
- Melagraki G, Afantitis A. Ligand and structure based virtual screening strategies for hit-finding and optimization of hepatitis C (HCV) inhibitors. Curr Med Chem 2011;18:2612–19
- Talele TT, Arora P, Kulkarni SS, et al. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem 2010;18:4630–8
- Kim J, Kim K-S, Kim D-E, Chong Y. Identification of Novel HCV RNA-dependent RNA polymerase inhibitors using pharmacophore-guided virtual screening. Chem Biol Drug Des 2008;72:585–91
- Melagraki G, Afantitis Α, Sarimveis H, et al. Identification of a series of novel derivatives as potent HCV inhibitors by a ligand-based virtual screening optimized procedure. Bioorg Med Chem 2007;15:7237–47
- Musmuca I, Caroli A, Mai A, et al. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. J Chem Inf Model 2010;50:662–76
- Zhu J, Li Y, Yu H, et al. Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses. Comb Chem High Throughput Screen 2012;15:439–50
- Ryu K, Kim ND, Choi SI, et al. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorg Med Chem 2009;17:2975–82
- Louise-May S, Yang W, Nie X, et al. Discovery of novel dialkyl substituted thiophene inhibitors of HCV by in silico screening of the NS5B RdRp. Bioorg Med Chem Lett 2007;17:3905–9
- Li T, Froeyen M, Herdewijn P. Insight into ligand selectivity in HCV NS5B polymerase: molecular dynamics simulations, free energy decomposition and docking. J Mol Model 2010;16:49–59
- Wang X, Yang W, Xu X, et al. Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics. Curr Med Chem 2010;17:2788–803
- Davis BC, Thorpe IF. Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase. Proteins 2013;81:40–52
- Su L, Li L, Li Y, et al. Simple and accurate approaches to predict the activity of benzothiadiazine derivatives as HCV inhibitors. Med Chem Res 2012;21:2079–96
- Ismail MAH, Abou El Ella DA, Abouzid KAM, Mahmoud AH. Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives. Bioorg Med Chem 2012;20:2455–78
- Stammers TA, Coulombe R, Rancourt J, et al. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors. Bioorg Med Chem Lett 2013;23:2585–9
- Stammers TA, Coulombe R, Duplessis M, et al. Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay. Bioorg Med Chem Lett 2013;23:6879–85
- MacroModel, version 9.7. New York (NY): Schrödinger, LLC; 2012
- Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 2001;105:6474–87
- LigPrep, version 2.3. New York (NY): Schrödinger, LLC; 2012
- Schrödinger Suite 2012 Protein Preparation Wizard, Epik version 2.3, Schrödinger, LLC, New York, NY, 2012; Impact version 5.8, Schrödinger, LLC, New York, NY, 2012; Prime version 3.1, Schrödinger, LLC, New York, NY, 2012
- Shelley JC, Cholleti A, Frye LL, et al. Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 2007;21:681–91
- Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 2001;105:6474–87
- Kontoyianni M, McClellan LM, Sokol GS. Evaluation of docking performance: comparative data on docking algorithms. J Med Chem 2004;47:558–65
- Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity – a rapid access to atomic charges. Tetrahedron 1980;36:3219–28
- Purcell WP, Singer JA. A brief review and table of semiempirical parameters used in the Hueckel molecular orbital method. J Chem Eng Data 1967;12:235–46
- SYBYL/QSAR and COMFA, molecular modeling Software packages, version 8.0, 2007, Tripos Inc, 1699 South Hanley Rd, St. Louis, MO; 2007
- Clark M, Cramer III DR, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J Comput Chem 1989;10:982–1012
- Frank I, Feikema J, Constantine N, Kowalski B. Prediction of product quality from spectral data using the partial least-squares method. J Chem Inf Comput Sci 1984;24:20–4
- Rännar S, Lindgren F, Geladi P, Wold S. A PLS kernel algorithm for data sets with many variables and fewer objects. Part 1: theory and algorithm. J Chemometrics 1994;8:111–25
- Cramer III RD, Bunce JD, Patterson DE, Frank IE. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct-Act Relat 1988;7:18–25
- Hawkins DM, Basak SC, Mills D. Assessing model fit by cross-validation. J Chem Inf Comput Sci 2003;43:579–86
- Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol Inf 2010;29:476–88
- Roy K, Chakraborty P, Mitra I, et al. Some case studies on application of ‘‘’’ metrics for judging quality of quantitative structure–activity relationship predictions: emphasis on scaling of response data. J Comput Chem 2013;34:1071–82
- Roy PP, Paul S, Mitra I, Roy K. On two novel parameters for validation of predictive QSAR models. Molecules 2009;14:1660–701
- Melagraki G, Afantitis A. Enalos KNIME nodes: exploring corrosion inhibition of steel in acidic medium. Chem Intel Lab Syst 2013;123:9–14
- Zhang S, Golbraikh A, Oloff S, et al. Novel automated lazy learning QSAR (ALL-QSAR) approach: method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models. J Chem Inf Model 2006;46:1984–95
- Papa E, Kovarich S, Gramatica P. Development, validation and inspection of the applicability domain of QSPR models for physicochemical properties of polybrominated diphenyl ethers. QSAR Comb Sci 2009;28:790–6
- Liu H, Yao X, Gramatica P. The applications of machine learning algorithms in the modeling of estrogen-like chemicals. Comb Chem High Throughput Screening 2009;12:490–6
- Melagraki G, Afantitis A. Enalos InSilicoNano platform: an online decision support tool for the design and virtual screening of nanoparticles. RSC Advances 2014;4:50713–25
- Enalos KNIME Nodes (Novamechanics Ltd). Available from: http://www.novamechanics.com/knime.php
- Love RA, Parge HE, Yu X, et al. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J Virol 2003;77:7575–81
- Sethi KK, Verma SM. A systematic quantitative approach to rational drug design and discovery of novel human carbonic anhydrase IX inhibitors. J Enzyme Inhib Med Chem 2014;29:571–81
- Melagraki G, Afantitis A, Sarimveis H, et al. QSAR study on para-substituted aromatic sulfonamides as carbonic anhydrase II inhibitors using topological information indices. Bioorg Med Chem 2006;14:1108–14
- Singh S, Supuran CT. 3D-QSAR CoMFA studies on sulfonamide inhibitors of the Rv3588c β-carbonic anhydrase from Mycobacterium tuberculosis and design of not yet synthesized new molecules. J Enzyme Inhib Med Chem 2014;29:449–55
- Agelis G, Resvani A, Koukoulitsa C, et al. Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent angiotensin II receptor blockers. Eur J Med Chem 2013;62:352–70
- Ghasemi JB, Meftah, N. Docking, CoMFA and CoMSIA studies of a series of sulfonamides derivatives as carbonic anhydrase I inhibitors. J Enzyme Inhib Med Chem 2013;28:320–7
- Mouchlis VD, Melagraki G, Mavromoustakos T, et al. Molecular modeling on pyrimidine-urea inhibitors of TNF-α production: an integrated approach using a combination of molecular docking, classification techniques, and 3D-QSAR CoMSIA. J Chem Inf Model 2012;52:711–23
- Cichero E, Bruno O, Fossa P. Docking-based CoMFA and CoMSIA analyses of tetrahydro-β-carboline derivatives as type-5 phosphodiesterase inhibitors. J Enzyme Inhib Med Chem 2012;27:730–43
- Durdagi S, Papadopoulos M, Papahadjis D, Mavromoustakos T. Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity. Bioorg Med Chem Lett 2007;17:6754–63
- Melagraki G, Afantitis A, Sarimveis H, et al. A novel RBF neural network training methodology to predict toxicity to Vibrio fischeri. Mol Div 2006;10:213–21
- Afantitis A, Melagraki G, Sarimveis H, et al. Development and evaluation of a QSPR model for the prediction of diamagnetic susceptibility. QSAR Comb Sci 2008;27:432–6
- Nesmerak K, Toropov AA, Toropova AP, et al. SMILES-based quantitative structure-property relationships for half-wave potential of N-benzylsalicylthioamides. Eur J Med Chem 2013;67:111–14
- Vaidya A, Jain AK, Kumar P, et al. Predicting anti-cancer activity of quinoline derivatives: CoMFA and CoMSIA approach. J Enzyme Inhib Med Chem 2011;26:854–61
- Durdagi S, Mavromoustakos T, Papadopoulos MG. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullarene-based HIV-1 PR inhibitors. Bioorg Med Chem Lett 2008;18:6283–9
- Murumkar PR, Sharma MK, Shinde AC, Bothara KG. Three-dimensional quantitative structure-activity relationship CoMFA/CoMSIA on pyrrolidine-based tartrate diamides as TACE inhibitors. Med Chem Res 2013;22:4192–201
- Yuan J, Pu Y, Yin L. Docking-based three-dimensional quantitative structure-activity relationship (3D-QSAR) predicts binding affinities to aryl hydrocarbon receptor for polychlorinated dibenzodioxins, dibenzofurans, and biphenyls. Environ Toxicol Chem 2013;32:1453–8
- Hao M, Li Y, Zhang S-W, Yang W. Investigation on the binding mode of benzothiophene analogues as potent factor IXa (FIXa) inhibitors in thrombosis by CoMFA, docking and molecular dynamic studies. J Enzyme Inhib Med Chem 2011;26:792–804
- Golbraikh A, Tropsha A. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. Mol Div 2002;5:231–43
- Kar S, Roy K. How far can virtual screening take us in drug discovery? Expert Opin Drug Discov 2013;8:245–61
- Ojha PK, Roy K. First report on exploring structural requirements of alpha and beta thymidine analogs for PfTMPK inhibitory activity using in silico studies. Biosystems 2013;113:177–95
- De Bethune MP, De Meyer S, Hertogs K, et al. Small molecule entry inhibitors, Patent US7429677B2; 30-09-2008